The company is trading at $1.08 and looks to improve on FDA granting orphan drug designation.
AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
https://finance.yahoo.com/news/avrobio-receives-orphan-drug-designation-110000405.html